How has the regen-cov and ronapreve market evolved, and where is it heading next?
The regen-cov and ronapreve market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to demand for personalized medicine, an increase in the prevalence of lifestyle-related infectious diseases, growth of generic antiviral drugs, demand for vector-borne disease treatments, and the demand for preventive healthcare.
The regen-cov and ronapreve market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to the rising prevalence of chronic and complex diseases, rising incidence of infectious diseases, rising prevalence of viral infections, rising incidence of zika virus infections, and rising incidence of respiratory infections. Major trends in the forecast period include the adoption of bispecific antibodies, remote diagnostics and monitoring, a focus on emerging and neglected viral infections, advances in diagnostic testing, and the adoption of molecular diagnostic techniques.
Get Your Free Sample of The Global Regen-cov And Ronapreve Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20287&type=smp
What are the key drivers behind the rapid expansion of the regen-cov and ronapreve market?
Rising incidence of infectious diseases is expected to propel growth of the regen-cov and ronapreve market going forward. Infectious diseases are illnesses caused by harmful microorganisms like bacteria, viruses, fungi, or parasites, which spread through contact, air, water, or contaminated food. The rising incidence of infectious diseases is fueled by climate change, which expands the range of vectors like mosquitoes, and globalization, where increased travel rapidly spreads pathogens across borders. Regen-Cov (Ronapreve) is a monoclonal antibody cocktail used to treat COVID-19, targeting the SARS-CoV-2 virus to prevent severe illness, particularly in high-risk patients. For instance, in November 2024, according to the National Library of Medicine (NLM), a US-based government agency, between 5 and 11 November, 167,369 people in England tested positive for COVID-19, marking an 11% increase from the previous week. The positivity rate remained steady at 9.6%, close to the 9.7% reported the week before. Therefore, the rising incidence of infectious diseases is driving the growth of the regen-cov and ronapreve market.
What is the segmentation for the regen-cov and ronapreve market?
The regen-cov and ronapreve market covered in this report is segmented –
1) By Clinical Indication: Treatment Of Mild To Moderate COVID-19; Post-Exposure Prophylaxis (PEP); Pre-Exposure Prophylaxis (PrEP)
2) By Distribution Channel: Hospitals; Outpatient Clinics; Home Healthcare
3) By End User: Pediatric; Adult; Geriatric
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/regen-cov-and-ronapreve–global-market-report
Who are the most influential companies in the regen-cov and ronapreve market?
Major companies operating in the regen-cov and ronapreve market are F. Hoffmann-La Roche AG; Regeneron Pharmaceuticals
What are the most influential trends expected to drive the regen-cov and ronapreve market forward?
The key trend in the regen-cov and ronapreve market is obtaining regulatory approvals to expand its use for additional indications and in various regions, which can drive market growth and adoption. Regulatory approvals refer to the formal authorization granted by health authorities, such as the FDA or EMA, allowing a drug or treatment to be legally sold and used after demonstrating safety, efficacy, and quality through clinical evaluations. For instance, F.Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, received approval for Ronapreve, a monoclonal antibody treatment for the treatment of non-hospitalized COVID-19 patients and for prophylaxis against the disease, in collaboration with Regeneron Pharmaceuticals, a US-based biotechnology company. It is indicated for adults and adolescents aged 12 and older who are at increased risk of severe COVID-19 but do not require supplemental oxygen. Clinical studies demonstrated that Ronapreve significantly reduces the risk of hospitalization and death, as well as preventing symptomatic COVID-19 in individuals exposed to infected persons.
What are the major regional insights for the regen-cov and ronapreve market, and which region holds the top position?
North America was the largest region in the regen-cov and ronapreve market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the regen-cov and ronapreve market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Regen-cov And Ronapreve Market Report 2025 Offer?
The regen-cov and ronapreve market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Regen-cov and ronapreve are monoclonal antibody therapy combining casirivimab and imdevimab, designed to neutralize SARS-CoV-2 by targeting its spike protein, preventing cell entry. It is authorized for treating mild-to-moderate COVID-19 in high-risk patients and as post-exposure prophylaxis, reducing hospitalization and death rates effectively.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20287
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
